title: The role of immunotherapy in solid tumors: report from the Campania Society of Oncology Immunotherapy (SCITO) meeting, Naples 2014.
abstract: The therapeutic approach to advanced or metastatic solid tumors, either with chemotherapy or targeted therapies, is mainly palliative. Resistance to chemotherapy occurs very frequently and is one of the most important reasons for disease progression. Immunotherapy has the potential to mount an ongoing, dynamic immune response that can kill tumor cells for an extended time after the conventional therapy has been administered. Such a long-lasting response is potentially able to completely eradicate tumor cells, rather than producing only a temporary killing of cells. The most promising immune-based treatments are monoclonal antibodies that act as checkpoint inhibitors (e.g. ipilimumab and nivolumab), adoptive cell therapy (e.g. T-cells expressing chimeric antigen receptors) and vaccines (e.g. sipuleucel-T). Ipilimumab is currently approved for the treatment of metastatic melanoma and sipuleucel-T is approved for advanced prostate cancer. There is great interest in immunotherapy in other solid tumors, potentially used alone or in a multimodal fashion with chemotherapy and/or biological drugs. In this paper, we review recent advances in immuno-oncology in solid malignancies (except melanoma) as were discussed at the inaugural meeting of the Campania Society of Oncology Immunotherapy (SCITO).
authors.affiliation: Unit of Melanoma, Cancer Immunotherapy and Innovative Therapies, Istituto Nazionale Tumori Fondazione "G. Pascale", Via Mariano Semmola, 80131, Naples, Italy. paolo.ascierto@gmail.com.
authors.forename: Paolo A
authors.initials: PA
authors.lastname: Ascierto
authors.affiliation: Unit of Oncology, Ospedale "San Giovanni di Dio", Frattamaggiore, NA, Italy. lelloaddeo@alice.it.
authors.forename: Raffaele
authors.initials: R
authors.lastname: Addeo
authors.affiliation: Unit of Medical Oncology, Dipartimento di Oncopneumoematologia, A.O.R.N. "A. Cardarelli", Naples, Italy. cartenigiacomo@gmail.com.
authors.forename: Giacomo
authors.initials: G
authors.lastname: Cartenì
authors.affiliation: Department of Oncology, A.O. "G. Rummo", Benevento, Italy. b.daniele@libero.it.
authors.forename: Bruno
authors.initials: B
authors.lastname: Daniele
authors.affiliation: Unità Oncologia Medica Senologica, Istituto Nazionale Tumori Fondazione "G. Pascale", Naples, Italy. m.delaurentiis@istitutotumori.na.it.
authors.forename: Michele
authors.initials: M
authors.lastname: De Laurentis
authors.affiliation: Department of Oncology, A.O.R.N. "S. Anna e S. Sebastiano", Caserta, Italy. ianniellog@libero.it.
authors.forename: Giovanni Pietro
authors.initials: GP
authors.lastname: Ianniello
authors.affiliation: Unità Oncologia Medica Toraco-Polmonare, Istituto Nazionale Tumori Fondazione "G. Pascale", Naples, Italy. a.morabito@istitutotumori.na.it.
authors.forename: Alessandro
authors.initials: A
authors.lastname: Morabito
authors.affiliation: Department of Molecular and Clinical Endocrinology and Oncology, University "Federico II", Naples, Italy. giovpalm@unina.it.
authors.forename: Giovannella
authors.initials: G
authors.lastname: Palmieri
authors.affiliation: Dipartimento di Medicina e Chirurgia, A.O.U. "San Giovanni di Dio e Ruggi d'Aragona", University of Salerno, Salerno, Italy. spepe@unisa.it.
authors.forename: Stefano
authors.initials: S
authors.lastname: Pepe
authors.affiliation: Unità Sperimentazioni Cliniche, Istituto Nazionale Tumori Fondazione "G. Pascale", Napoli, Italy. f.perrone@istitutotumori.na.it.
authors.forename: Francesco
authors.initials: F
authors.lastname: Perrone
authors.affiliation: Dipartimento di Oncologia Uroginecologica, Istituto Nazionale Tumori Fondazione "G. Pascale", Naples, Italy. s.pignata@istitutotumori.na.it.
authors.forename: Sandro
authors.initials: S
authors.lastname: Pignata
authors.affiliation: Unit of Oncology, A.O.R.N. dei COLLI "Ospedali Monaldi-Cotugno-CTO", Naples, Italy. dott.vincenzomontesarchio@gmail.com.
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Montesarchio
mesh_terms: D002986:Clinical Trials as Topic; D003226:Congresses as Topic; D023381:Endpoint Determination; D006801:Humans; D007167:Immunotherapy; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy*